Cyclo Therapeutics Stock Analysis
| CYTH Stock | USD 0.77 0.03 3.75% |
Cyclo Therapeutics is overvalued with Real Value of 0.62 and Target Price of 0.95. The main objective of Cyclo Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Cyclo Therapeutics is worth, separate from its market price. There are two main types of Cyclo Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Cyclo Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Cyclo Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Cyclo |
Cyclo Stock Analysis Notes
About 40.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.9. Cyclo Therapeutics last dividend was issued on the 9th of December 2020. The entity had 1:100 split on the 9th of December 2020. Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida. Cyclo Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. For more info on Cyclo Therapeutics please contact Scott Fine at 386 418 8060 or go to https://cyclotherapeutics.com.Cyclo Therapeutics Quarterly Total Revenue |
|
Cyclo Therapeutics Investment Alerts
| Cyclo Therapeutics had very high historical volatility over the last 90 days | |
| Cyclo Therapeutics has some characteristics of a very speculative penny stock | |
| Cyclo Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.08 M. Net Loss for the year was (20.06 M) with profit before overhead, payroll, taxes, and interest of 1.04 M. | |
| Cyclo Therapeutics currently holds about 4.29 M in cash with (16.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51. | |
| Roughly 40.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Cyclo Therapeutics extends merger agreement with Rafael Holdings - Investing.com |
Cyclo Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cyclo Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Cyclo Largest EPS Surprises
Earnings surprises can significantly impact Cyclo Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-16 | 2024-03-31 | -0.2 | -0.15 | 0.05 | 25 | ||
2024-08-15 | 2024-06-30 | -0.15 | -0.21 | -0.06 | 40 | ||
2021-11-15 | 2021-09-30 | -0.67 | -0.6 | 0.07 | 10 |
Cyclo Therapeutics Thematic Classifications
In addition to having Cyclo Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | SyntheticsSynthetics production and silicon | |
 | Chemicals MakersChemicals for crops, soil, human, and animals |
Cyclo Stock Institutional Investors
| Shares | Princeton Global Asset Management Llc | 2024-12-31 | 0.0 |
Cyclo Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 26.19 M.Cyclo Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.74) | (1.65) | |
| Return On Capital Employed | (4.82) | (4.58) | |
| Return On Assets | (1.74) | (1.65) | |
| Return On Equity | (4.85) | (5.09) |
Management Efficiency
Cyclo Therapeutics has return on total asset (ROA) of (2.8249) % which means that it has lost $2.8249 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (226.6391) %, meaning that it created substantial loss on money invested by shareholders. Cyclo Therapeutics' management efficiency ratios could be used to measure how well Cyclo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The Cyclo Therapeutics' current Return On Tangible Assets is estimated to increase to -1.65. The Cyclo Therapeutics' current Return On Capital Employed is estimated to increase to -4.58. As of now, Cyclo Therapeutics' Intangible Assets are decreasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.34 | 0.32 | |
| Tangible Book Value Per Share | 0.34 | 0.32 | |
| Enterprise Value Over EBITDA | (1.02) | (1.07) | |
| Price Book Value Ratio | 4.91 | 7.66 | |
| Enterprise Value Multiple | (1.02) | (1.07) | |
| Price Fair Value | 4.91 | 7.66 | |
| Enterprise Value | 16 M | 16.8 M |
Understanding the operational decisions made by Cyclo Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Technical Drivers
As of the 7th of February, Cyclo Therapeutics shows the mean deviation of 4.14, and Risk Adjusted Performance of 0.0373. Cyclo Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cyclo Therapeutics Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cyclo Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cyclo Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Cyclo Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cyclo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cyclo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cyclo Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cyclo Therapeutics Outstanding Bonds
Cyclo Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cyclo Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cyclo bonds can be classified according to their maturity, which is the date when Cyclo Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
Cyclo Therapeutics Predictive Daily Indicators
Cyclo Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cyclo Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 10858.7 | |||
| Daily Balance Of Power | (0.38) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 0.79 | |||
| Day Typical Price | 0.78 | |||
| Price Action Indicator | (0.04) | |||
| Period Momentum Indicator | (0.03) |
Cyclo Therapeutics Forecast Models
Cyclo Therapeutics' time-series forecasting models are one of many Cyclo Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cyclo Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Cyclo Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Cyclo Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cyclo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cyclo Therapeutics. By using and applying Cyclo Stock analysis, traders can create a robust methodology for identifying Cyclo entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (21.43) | (20.36) | |
| Operating Profit Margin | (21.42) | (20.35) | |
| Net Loss | (21.43) | (20.36) | |
| Gross Profit Margin | 0.82 | 0.68 |
Current Cyclo Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cyclo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cyclo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 0.95 | Buy | 3 | Odds |
Most Cyclo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cyclo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cyclo Therapeutics, talking to its executives and customers, or listening to Cyclo conference calls.
Cyclo Stock Analysis Indicators
Cyclo Therapeutics stock analysis indicators help investors evaluate how Cyclo Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cyclo Therapeutics shares will generate the highest return on investment. By understating and applying Cyclo Therapeutics stock analysis, traders can identify Cyclo Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 1.5 M | |
| Total Stockholder Equity | 4.8 M | |
| Property Plant And Equipment Net | 929.3 K | |
| Cash And Short Term Investments | 9.2 M | |
| Shares Float | 15.9 M | |
| Cash | 9.2 M | |
| 200 Day M A | 0.9526 | |
| 50 Day M A | 0.6798 | |
| Total Current Liabilities | 8.5 M | |
| Stock Based Compensation | 736.9 K | |
| Common Stock Shares Outstanding | 16.3 M | |
| Free Cash Flow | -16.2 M | |
| Operating Income | -20.1 M | |
| Other Current Assets | 2.7 M | |
| Accounts Payable | 4.9 M | |
| Net Debt | -8.2 M | |
| Depreciation | 19.3 K | |
| Type | Common Stock | |
| Other Operating Expenses | 21.1 M | |
| Non Current Assets Total | 929.3 K | |
| E P S Estimate Current Quarter | -0.1567 | |
| Total Current Assets | 12.3 M | |
| Liabilities And Stockholders Equity | 13.2 M | |
| Income Before Tax | -20.1 M |
Complementary Tools for Cyclo Stock analysis
When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |